Health Capital Helsinki
  • Home
  • Why Helsinki Metropolitan
  • About
  • News
  • Events
  • Opportunities
  • Careers
  • Contact
  • Search
  • Menu Menu
Keksi Agency via City of Helsinki
Mar 21, 2023

Fighting Cancer Full Tilt

TILT Biotherapeutics, rising superstar of oncolytic immunotherapy

Helsinki-based biotech startup TILT Biotherapeutics is changing the face of oncolytic immunotherapy, fighting most types of cancer. The Finnish company boasts multiple best-in-class oncolytic viral therapies with TILT-123 in the lead. Learn more about the company’s innovative approach, how it all got started and what motivated TILT’s founder Akseli Hemminki, a cancer clinician, to become a entrepreneur.

TILT Biotherapeutics raised some eyebrows in February 2023 as the clinical-stage biotechnology company announced the final close of its EUR 22 million round. Akseli Hemminki, the founder-CEO of the Helsinki-based company, acknowledges that while biotech investments abroad may be bigger, for a Finnish biotech player such a funding round is, indeed, a big deal.

“Overall, we’ve secured more than 40 million euros in funding during our ten years of operations – which is a lot for a Finnish company in this sector.”

What’s notable in this latest round is that it includes €5.9 million equity from the European Innovation Council (EIC) Fund – as well as a €2.1 million grant from EIC’s Accelerator program. The EIC Fund is, in fact, TILT’s first significant international investor.

TILT Biotherapeutics funding announcement

Targeting cancer cells

But why is TILT Biotherapeutics making such big waves in the investment community? – The short answer: TILT is one of the rising superstars of oncolytic immunotherapy, fighting most types of cancer. The heart of TILT’s innovative approach is all about the use of armed oncolytic adenoviruses, using cytokines and other molecules to boost the patient’s immune response to better enable ‘Search & Destroy’ missions on cancer cells.

TILT is one of the rising superstars of oncolytic immunotherapy, fighting most types of cancer.

“We have our patented TILT technology – that is based on oncolytic viral therapies – which modifies the tumor microenvironment and eliminates its ability to suppress immune responses to cancer,” says Hemminki, a cancer clinician who has treated hundreds of cancer patients with oncolytic viruses.

“As a result, T cell therapies, such as checkpoint inhibitors and CAR T therapies, are enhanced.”

Towards becoming the global leader

At present, TILT boasts multiple best-in-class oncolytic viral therapies.

“In our pipeline, we have our lead therapeutic asset, TILT-123, which is a cytokine armed oncolytic adenovirus,” Akseli Hemminki says.

TILT-123 is currently in Phase 1 clinical trials as monotherapy and in combination with tumor infiltrating lymphocytes (TIL) therapy in Europe. There are also two other open trials, Hemminki reports.

TILT boasts multiple best-in-class oncolytic viral therapies.

“One is a combination with pembrolizumab, a checkpoint inhibiting antibody. This is open in Finland and the US.”

Then there is a combination trial with avelumab, which is open in Finland.

“Our vision is to become the leading company globally in oncolytic immunotherapy for enabling therapies based on T cells. This way, we can provide potentially curative treatment options for cancer patients,” Hemminki outlines the game plan. 

TILT Biotherapeutics team members
TILT Biotherapeutics

Photo: TILT Biotherapeutics team

The academic entrepreneur and clinician

Akseli Hemminki (born in 1973) certainly has an interesting resume – starting with the fact that he’s Professor of Oncology at the University of Helsinki as well as Founder & CEO of TILT – and still manages to treat patients a few hours a week.

Prior to founding TILT, he had co-founded Oncos Therapeutics Ltd (currently Targovax ASA), a company involved in the clinical development of oncolytic viruses.

“At Oncos, I wasn’t the CEO and eventually I started thinking about what it would be like to run my own company,” he looks back.

Having started TILT as a one-man-show in 2013, Hemminki now leads a team of 15 professionals – with definite international flavor.

“We have people from Portugal, Spain, Germany, Brazil, USA, England…,” he lists.

Innovation rooted in patient observation

The origin story of TILT is also intriguing in the sense that it’s rooted in patient observation much more than is the case with your average health/biotech startup. During 2007–2012, Hemminki pioneered individualized patient-by-patient use of oncolytic immunotherapy under the EU Advanced Therapy Directive – personally treating 290 patients using 10 different oncolytic adenoviruses during those years.

“That’s when I really became convinced of the impact of the oncolytic viruses,” he says.

Hemminki is also an inventor on more than 10 patent applications relating to oncolytic viruses, including all of TILT’s patents and has authored nearly 370 peer-reviewed manuscripts or book chapters on cancer research and oncolytic viruses. Looking back at his career so far, he says that the key thing has always been people.

“Working with young, smart people is always very energizing.”

When you’re to avoid the outcome of death with treatment, that is just an amazing feeling.

Matter of life and death

Another motivating factor is the possibility to do good: the benefits to the patients are often literally life-saving.

“When you see the patient file with the prognosis of death and you’re able to avoid that outcome with treatment, that is just an amazing feeling.”

And then there’s the kick of being an entrepreneur – a role that Hemminki says has grown on him over the years.

“Being an entrepreneur is something you don’t learn in any school – you learn the ropes by putting your best effort in, every single day.”

Homebase Helsinki adds benefits

Discussing the health/biotech ecosystem in Helsinki, Hemminki points out that collaboration with the University of Helsinki has been crucial in helping the local startups take wing.

“We’re one of the companies that is leasing research premises from the University,” he adds.

Also, there is ample talent available in the Helsinki Metropolitan Area with reasonable labor costs.

“We have an affiliate in Boston, too, but it’s less expensive to do most things right here in Helsinki.”

TILT Biotherapeutics logo

Fast Facts

Name: TILT Biotherapeutics

Product:
Cancer-fighting armed oncolytic adenoviruses

Founded:
2013

Team size:
15

Target customer/market:
Pharma companies

Text: Sami J. Anteroinen

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn

More news

Health Capital Helsinki

Event speakers at the stage of the Radical Health Festival Helsinki in 2024Pekka Hannila / Helsinki Expo and Convention Centre

Helsinki to host the 3rd edition of the Radical Health Festival Helsinki in 2026

https://ecshuqpetk9.exactdn.com/wp-content/uploads/2025/01/2M1A2739-1.jpg?strip=all&lossy=1&quality=55&ssl=1 1365 2048 Saana Lehtinen https://ecshuqpetk9.exactdn.com/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png Saana Lehtinen2025-01-27 11:21:122025-01-27 11:40:35Helsinki to host the 3rd edition of the Radical Health Festival Helsinki in 2026
A man with headphones and mobile phone in front of Oodi Central Library in HelsinkiAleksi Poutanen / Helsinki Partners

Free training materials: Cybersecurity for health startups and growth companies

Jan 7, 2025
https://ecshuqpetk9.exactdn.com/wp-content/uploads/2023/06/Man_at_Oodi_AleksiPoutanen.jpg?strip=all&lossy=1&quality=55&ssl=1 827 1240 Saana Lehtinen https://ecshuqpetk9.exactdn.com/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png Saana Lehtinen2025-01-07 13:17:452025-01-07 15:29:08Free training materials: Cybersecurity for health startups and growth companies
EsaDres team: Dr Marta Putrinš, Prof Karin Kogermann and Kairi Lorenz

EsaDres redefines wound care with tailored solutions

https://ecshuqpetk9.exactdn.com/wp-content/uploads/2024/10/EsaDres-team-2024.jpg?strip=all&lossy=1&quality=55&ssl=1 1016 2200 Saana Lehtinen https://ecshuqpetk9.exactdn.com/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png Saana Lehtinen2024-12-10 08:03:222024-12-12 14:13:44EsaDres redefines wound care with tailored solutions
All news

Health Capital Helsinki

Business Helsinki
Kansakoulukatu 3
00100 Helsinki
FINLAND

Privacy notice

Newsletter

Subscribe

Follow us

  • x
  • linkedin
Health Capital Helsinki
Scroll to top

We use cookies to give you the best experience on our website.

Find out more and set your preferences .

Powered by  GDPR Cookie Compliance
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential website cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Third party cookies

This website uses Twitter's and LinkedIn's cookies to help us improve our content and reach.

Please enable essential website cookies first so that we can save your preferences!

Privacy notice

You can read about how we use your data on our Privacy notice page.

Privacy notice